FDA approves first new Alzheimer’s drug in almost 20 yearsJune 7, 2021
Usefulness of aducanumab is disputed but US approval will trigger push to make it available globally
A controversial new drug for Alzheimer’s disease, the first in nearly 20 years, was approved in the US on Monday, which will trigger pressure to make it available worldwide in spite of mixed evidence over its efficacy.
While doctors, patients and the organisations that support them are desperate for treatments that can slow mental deterioration, the usefulness of the new drug,aducanumab, is disputed by scientists. Two trials were stopped in March 2019 because the drugs appeared not to work. The manufacturer, Biogen, said the drugs were unlikely to improve people’s memory and thinking.